Clarkston Capital Partners’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-1,500
Closed -$207K 154
2025
Q4
$207K Buy
+1,500
New +$196K ﹤0.01% 172
2021
Q2
Sell
-5,180
Closed -$443K 187
2021
Q1
$443K Buy
+5,180
New +$465K 0.01% 108

Other funds holding NVS

Clarkston Capital Partners's NVS Position: Q1 2026 in Review

Clarkston Capital Partners sold out of Novartis (NVS) in Q1 2026, closing a stake of 1,500 shares — an estimated $207K sold.

Clarkston Capital Partners first reported a position in NVS in Q1 2021 and held it in 2 quarters. The position peaked at $443K in Q1 2021. 1,603 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

  • Clarkston Capital Partners reported no remaining Novartis position as of Q1 2026 after selling out during the quarter.
  • Clarkston Capital Partners sold 1,500 Novartis shares in Q1 2026, an estimated $207K.
  • Clarkston Capital Partners first reported a position in Novartis in Q1 2021 and held it in 2 quarters.
  • Clarkston Capital Partners's Novartis position peaked at $443K in Q1 2021.
  • 1,603 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on Clarkston Capital Partners's 13F filing for Q1 2026, filed 14 May 2026.